HypoglycemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

586 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Galactosemia Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp46

Immediate priorities

›Immediate stabilization

›Airway protection triggers

›GCS < 8

›Refractory seizures

›Persistent vomiting with aspiration risk

›Breathing targets

›SpO2 94% to 98%

›End-tidal CO2 monitoring if intubated

›Circulation priorities

›Cardiac monitor

›IV access x 1 to 2

›If shock, large bore IV x 2

›Point-of-care glucose

›Altered mental status

›Seizure

›Syncope

›Focal neurologic deficit mimic

›Diaphoresis and tremor

›Temperature

›Hypothermia as contributor

›Sepsis consideration if febrile or hypothermic

Bedside decision points

›Time-critical decisions

›If severe symptoms, treat before full workup

›Seizure

›Coma

›Hemodynamic instability

›If no IV access, glucagon pathway

›IM glucagon option

›IN glucagon option

›If on sulfonylurea, octreotide pathway

›Rebound risk after dextrose

›Prolonged monitoring need

›If alcohol use or malnutrition, thiamine adjunct

›Wernicke risk context

›Coexisting hypoglycemia triggers evaluation

Monitoring and targets

›Monitoring plan

›Recheck glucose frequency

›Every 5 to 15 minutes until stable

›Every 30 to 60 minutes after stabilization

›Target glucose range after treatment

›5.0 to 10.0 mmol/L

›Avoid overshoot above 11.1 mmol/L in most cases

›Recurrent episode triggers

›Repeat neuroglycopenic symptoms

›Falling trend despite carbohydrates

›Long-acting insulin or secretagogue exposure

02History/hx72

Symptom pattern and timing

›Presentation profile

›Symptom categories

›Autonomic

›Tremor

›Palpitations

›Anxiety

›Diaphoresis

›Hunger

›Neuroglycopenic

›Confusion

›Behavioral change

›Visual disturbance

›Dysarthria

›Weakness

›Seizure

›Coma

›Timeline

›Symptom onset time

›Relation to meals

›Relation to exercise

›Nocturnal episodes

›Response pattern

›Improvement with carbohydrates

›Rebound after initial improvement

Diabetes therapies and exposures

›Medication and dosing context

›Insulin details

›Type

›Rapid acting

›Short acting

›Intermediate

›Long acting

›Last dose time

›Recent dose changes

›Injection site and rotation

›Secretagogues

›Sulfonylurea type

›Last dose time

›Renal impairment context

›Other glucose-lowering agents

›GLP-1 receptor agonist with reduced intake

›SGLT2 inhibitor with reduced intake

›Metformin with sepsis or renal failure context

›Accidental exposure

›Pediatric ingestion possibility

›Medication mix-ups

›Intentional overdose concern

›Access to insulin or oral agents

›Missing pills or vials

Risk factors and precipitating illness

›Predisposition factors

›Reduced intake

›Missed meals

›Vomiting

›Poor appetite

›Increased utilization

›Strenuous exercise

›Shivering or hypothermia

›Reduced clearance

›CKD

›Hepatic failure

›Counter-regulatory failure

›Adrenal insufficiency

›Hypopituitarism

›Infection and systemic illness

›Sepsis

›Pneumonia

›UTI

›Substance context

›Alcohol intake timing

›Stimulant use with poor intake

›Prior severe hypoglycemia

›Hypoglycemia unawareness

›Recent tight glycemic targets

03Physical Exam/exam54

General and neurologic

›Key exam domains

›Vital signs

›Tachycardia

›Hypertension early

›Hypotension in sepsis or overdose co-tox

›Hypothermia

›Mental status

›Agitation

›Confusion

›Somnolence

›Coma

›Neurologic screen

›Focal deficits mimic

›Dysarthria

›Ataxia

›Seizure activity

›Autonomic signs

›Diaphoresis

›Tremor

›Mydriasis

›Hydration and nutrition

›Dehydration signs

›Cachexia or malnutrition signs

Targeted findings for causes

›Etiology clues

›Infection signs

›Fever

›Rigors

›Lung findings

›CVA tenderness

›Hepatic failure signs

›Jaundice

›Ascites

›Asterixis

›Adrenal insufficiency signs

›Hyperpigmentation

›Orthostasis

›Abdominal pain

›Toxidrome screening

›Beta-blocker features

›Salicylate features

›Ethanol intoxication

›Injection site exam

›Lipohypertrophy

›Unexpected absorption site

PITFALLS

›Common pitfalls

›Normal appearance after prehospital glucose

›Persistent cause untreated

›Rebound risk with secretagogues

›Stroke mimic anchoring

›Glucose check before thrombolysis pathway

›Hypothermia masking symptoms

›Slow glucose recovery

›Beta-blocker masking autonomic symptoms

›Neuroglycopenic-only presentation

04Differential Diagnosis/ddx50

Primary diagnosis and related states

›Hypoglycemia etiologies

›Drug-induced hypoglycemia

›Insulin excess

›ICD-10 T38.3X1A

›SNOMED CT insulin overdose concept

›Sulfonylurea-related

›ICD-10 T38.3X1A

›Prolonged recurrent episodes

›Other agents

›Quinolones association

›Pentamidine association

›Critical illness hypoglycemia

›Sepsis related

›ICD-10 A41.9 with hypoglycemia context

›Hepatic failure related

›ICD-10 K72.90 with hypoglycemia context

›Renal failure related

›ICD-10 N17.9 or N18.x with reduced clearance context

›Endocrine deficiency

›Adrenal insufficiency

›ICD-10 E27.1 or E27.2

›Hypopituitarism

›ICD-10 E23.0

›Endogenous hyperinsulinism

›Insulinoma

›ICD-10 D13.7

›Post-bariatric hypoglycemia

›ICD-10 K91.2 with hypoglycemia context

›Reactive hypoglycemia

›Postprandial episodes

›Normal fasting glucose outside episodes

›Hypoglycemia unawareness

›Autonomic symptom blunting

›Recurrent severe episodes

Mimics of hypoglycemia symptoms

›Look-alikes

›Stroke or TIA

›ICD-10 I63.x or G45.x

›Seizure disorder

›ICD-10 G40.x

›Intoxication

›Ethanol

›Sedative-hypnotic

›Opioid

›Syncope causes

›Arrhythmia

›Vasovagal

›Panic attack

›ICD-10 F41.0

›Thyrotoxicosis

›ICD-10 E05.x

05Laboratory Tests/lt60

Core labs by scenario

›Laboratory evaluation strategy

›Confirmatory plasma glucose

›If POC inconsistent with presentation

›If persistent symptoms despite treatment

›Electrolytes and renal function

›Sodium

›Pseudohyponatremia context

›Potassium

›Insulin driven intracellular shift risk

›Creatinine and eGFR

›Drug accumulation risk

›Liver panel

›AST and ALT

›Hepatic gluconeogenesis failure context

›Bilirubin

›Liver failure severity context

›CBC

›Infection screening context

›Anemia contributing to symptoms context

›Venous blood gas

›If acidosis concern

›If sepsis concern

Focused endocrine and tox labs

›Cause-directed labs

›Serum ketones or beta-hydroxybutyrate

›Low ketones with hyperinsulinemia context

›High ketones with starvation or alcohol context

›Lactate

›Sepsis context

›Metformin associated lactic acidosis context

›Cortisol

›If adrenal insufficiency suspected

›If refractory hypoglycemia

›TSH and free T4

›If hypopituitarism suspected

›Serum ethanol

›If altered and exposure possible

›Acetaminophen level

›If overdose unclear

›Salicylate level

›If tachypnea or mixed acid base concern

Hypoglycemia workup during an episode

›Critical sample concept

›Indication

›Recurrent unexplained episodes

›Non-diabetic hypoglycemia

›Tests collected during low glucose

›Insulin

›Elevated suggests hyperinsulinemia

›C-peptide

›Elevated suggests endogenous insulin secretion

›Proinsulin

›Elevated supports insulinoma or secretagogue effect

›Sulfonylurea screen

›Detects secretagogue exposure

›Beta-hydroxybutyrate

›Suppressed with hyperinsulinemia

›Cortisol

›Low suggests adrenal insufficiency

›Interpretation pitfalls

›Samples after dextrose reduce yield

›Insulin assays vary by analog type

06Diagnostic Tests/dt48

Scoring Systems

›Bedside diagnostic frameworks

›Whipple triad

›Symptoms consistent with hypoglycemia

›Low measured glucose at the time of symptoms

›Symptom resolution after glucose correction

›Severity classification

›Clinically significant hypoglycemia below 3.0 mmol/L

›Severe hypoglycemia requiring assistance

›Recurrent hypoglycemia within 24 hours

›Risk stratification elements

›Long-acting insulin or sulfonylurea exposure

›CKD or hepatic failure

›Poor oral intake

›Limited home supervision

MRI

›MRI indications and roles

›Neuroimaging role

›Persistent focal deficit after normoglycemia

›Persistent encephalopathy after normoglycemia

›Pituitary evaluation

›Suspected hypopituitarism

›Multiple pituitary hormone deficits signs

›Pancreatic evaluation

›Suspected insulinoma with nondiagnostic CT

›Multiphase pancreatic MRI protocol

›CT indications and roles

›Head CT

›Persistent neurologic deficit after correction

›Trauma from collapse

›Anticoagulation with fall

›Abdomen CT

›Suspected insulinoma localization

›Suspected malignancy related hypoglycemia

›Chest CT

›Suspected infection source

›Suspected malignancy related hypoglycemia

Ultrasound (or US)

›Ultrasound applications

›Focused cardiac ultrasound

›Shock evaluation

›Volume status context

›Lung ultrasound

›Pneumonia screening context

›Pulmonary edema screening context

›Abdominal ultrasound

›Liver disease findings

›Biliary source of infection

›Endoscopic ultrasound referral context

›Insulinoma localization pathway

›Surgical planning support

07Disposition/dispo29

Admission and observation criteria

›Level of care decisions

›ICU criteria

›Refractory hypoglycemia requiring continuous dextrose infusion

›Recurrent seizures

›Airway compromise

›Severe co-tox ingestion

›Shock or sepsis with vasopressor need

›Inpatient or observation criteria

›Sulfonylurea exposure

›Long-acting insulin exposure

›Recurrent episode in ED

›Inability to maintain oral intake

›No reliable supervision

›Significant renal or hepatic dysfunction

Discharge criteria and follow-up

›Safe discharge requirements

›Sustained euglycemia

›Stable glucose above 4.0 mmol/L for a clinically appropriate observation period

›No downward trend after last carbohydrate

›Cause addressed

›Medication adjustment plan

›Intercurrent illness plan

›Capacity and supports

›Reliable caregiver if prior severe symptoms

›Access to food and glucose source

›Access to glucose monitoring

›Follow-up plan

›Primary care or diabetes clinician within 24 to 72 hours

›Medication reconciliation documented

›Education completed and understood

08Treatment/t101

Immediate glucose correction

›Rapid correction pathways

›Oral carbohydrate pathway

›Indications

›Awake

›Able to swallow

›Low aspiration risk

›Dosing

›Fast-acting carbohydrate 15 g

›Glucose tablets equivalent dosing

›Sweet beverage volume equivalent dosing

›Recheck glucose after 15 minutes

›If below 4.0 mmol/L, repeat 15 g

›If above 4.0 mmol/L, long-acting carbohydrate snack

›IV dextrose pathway

›Indications

›Altered mental status

›Seizure

›Unable to swallow

›Persistent symptoms after oral therapy

›Adult bolus options

›Dextrose 50% 25 g IV

›Volume 50 mL

›If recurrent, transition to infusion

›Dextrose 10% 100 to 250 mL IV

›Lower extravasation risk

›Repeat based on glucose response

›Pediatric bolus

›Dextrose 10% 2 mL/kg IV

›Maximum 250 mL

›Avoid D50 in small children due to hyperosmolar injury risk

›Glucagon pathway

›Indications

›No IV access

›Prehospital or outpatient rescue

›Dosing

›Glucagon 1 mg IM

›Adult standard dosing

›Pediatric weight-based dosing per local protocol

›Intranasal glucagon 3 mg

›Single-use device

›Not dependent on inhalation

›Limitations

›Reduced efficacy with depleted glycogen

›Alcohol use

›Starvation

›Advanced liver disease

Prevention of recurrence

›Recurrence prevention strategy

›Long-acting carbohydrate after correction

›Complex carbohydrate and protein snack

›Meal as soon as feasible

›Dextrose infusion when needed

›Dextrose 10% infusion start

›100 to 200 mL/hour initial range

›Titrate every 10 to 20 minutes to target 5.0 to 10.0 mmol/L

›If high requirement, central access consideration

›Dextrose 20% via central line

›Monitor for phlebitis and extravasation

›Electrolyte monitoring

›Potassium trend after insulin driven shift

›Phosphate trend in prolonged correction

Sulfonylurea and secretagogue hypoglycemia

›Secretagogue-specific therapy

›Octreotide

›Rationale

›Suppresses insulin release from beta cells

›Reduces rebound hypoglycemia after dextrose

›Adult dosing

›Octreotide 50 micrograms SC or IV

›Repeat every 6 hours as needed

›Typical course 12 to 24 hours based on recurrence risk

›Pediatric dosing

›Octreotide 1 to 1.5 micrograms/kg SC or IV

›Repeat every 6 hours as needed

›Monitoring

›Glucose trend for rebound

›Bradycardia risk

›GI side effects

›Activated charcoal

›Indications

›Recent ingestion with protected airway

›Large ingestion concern

›Dose

›1 g/kg orally

›Maximum 50 g

Refractory and special-cause therapies

›Cause-directed adjuncts

›Thiamine adjunct

›Indications

›Alcohol use disorder

›Malnutrition

›Prolonged vomiting

›Dosing

›Thiamine 100 mg IV

›Give early in high-risk patients

›Adrenal insufficiency therapy

›If strongly suspected or hypotension

›Hydrocortisone 100 mg IV

›Repeat 50 mg IV every 6 hours based on clinical course

›Draw cortisol first if feasible without delaying resuscitation

›Beta-blocker co-tox suspicion

›Glucagon infusion consideration

›After bolus response

›Consult toxicology

09Special Populations/sp48

Pregnancy

›Pregnancy-specific considerations

›Maternal fetal risk

›Fetal distress risk with maternal hypoglycemia

›Maternal seizure and trauma risk

›Diabetes in pregnancy context

›Lower glucose targets with higher hypoglycemia risk

›Nausea and vomiting lowering intake

›Treatment safety

›Oral glucose preferred when safe

›IV dextrose safe when needed

›Glucagon acceptable for rescue

›Disposition modifiers

›Obstetric consultation for recurrent severe episodes

›Fetal assessment consideration in viable gestation with maternal collapse

Geriatric

›Older adult considerations

›Atypical presentation

›Confusion without adrenergic symptoms

›Falls as presenting feature

›Higher harm risk

›Arrhythmia risk

›Fracture and head injury risk

›Medication risk

›Sulfonylurea sensitivity

›CKD related accumulation

›Disposition modifiers

›Lower threshold for observation or admission

›Home support assessment emphasis

Pediatrics

›Pediatric considerations

›Common causes by age

›Neonate

›Hyperinsulinism

›Inborn errors of metabolism

›Toddler

›Accidental ingestion

›Ketotic hypoglycemia

›Adolescent

›Diabetes treatment mismatch

›Eating disorder context

›Dextrose dosing safety

›Dextrose 10% 2 mL/kg IV bolus

›Avoid high concentration peripheral infusion

›Critical sample importance

›Recurrent or unexplained episodes

›Metabolic consultation pathway

›Disposition modifiers

›Admission for suspected ingestion

›Admission for unclear cause

›Social safety evaluation when neglect concern

10Background/b43

Epidemiology

›Epidemiologic features

›Diabetes-related hypoglycemia is most common cause in ED settings

›Insulin treated diabetes highest risk group

›Secretagogue exposure associated with prolonged episodes

›High-risk contexts

›Older adults

›CKD

›Recent hospital discharge

›Harm associations

›Falls and trauma

›Arrhythmias

›Cognitive decline acceleration with recurrent severe episodes

Pathophysiology

›Mechanisms

›Neurogenic response

›Sympathetic activation triggers early symptoms

›Blunted response with recurrent episodes

›Neuroglycopenia

›Brain glucose dependence

›Seizure and coma at lower levels

›Counter-regulatory hormones

›Glucagon

›Epinephrine

›Cortisol

›Growth hormone

›Alcohol-related hypoglycemia

›Inhibits gluconeogenesis

›Glycogen depletion worsens risk

›Secretagogue rebound

›Ongoing insulin secretion despite dextrose correction

Therapeutic Considerations

›Treatment principles

›Rapid symptom reversal reduces neurologic injury risk

›Class I recommendation concept in resuscitation practice for immediate correction of documented hypoglycemia

›Oral therapy when safe reduces IV complications

›Aspiration risk screening required

›Dextrose concentration selection

›D10 reduces extravasation injury risk compared with D50

›D50 provides faster delivery when large deficits and IV access available

›Secretagogue management requires insulin suppression

›Octreotide reduces rebound episodes

›Observation duration longer than insulin-only hypoglycemia

›Avoid iatrogenic hyperglycemia

›Titrate infusion to physiologic targets

›Reassess need for ongoing dextrose frequently

11Patient Discharge Instructions/pdi29

copy discharge instructions

›Discharge instructions

›What happened

›Low blood sugar episode treated and improved

›Likely trigger identified when known

›What to do today

›Eat a meal with complex carbohydrates and protein

›Avoid skipping meals for the next 24 hours

›Check glucose more often for the next 24 hours

›Medication safety

›Do not take extra insulin or diabetes pills to compensate for high readings today

›Follow the medication adjustment plan provided

›Keep fast sugar available at all times

›How to treat a mild episode at home

›If glucose below 4.0 mmol/L, take fast sugar 15 g

›Recheck in 15 minutes

›Repeat 15 g if still below 4.0 mmol/L

›After recovery, eat a snack with complex carbohydrates

›When to return to the ED

›Confusion

›Seizure

›Fainting

›Glucose below 4.0 mmol/L that does not improve after two rounds of fast sugar

›Repeated lows in the same day

›Unable to keep food or fluids down

›Concern for medication overdose

›Follow-up

›Diabetes clinician or primary care follow-up within 24 to 72 hours

›Bring glucose logs or device data to the visit

›Review insulin and pill doses and meal plan

12References/r6

Clinical guidelines and evidence sources

›Reference set

›American Diabetes Association Standards of Medical Care in Diabetes current edition hypoglycemia definitions and management

›Endocrine Society clinical practice guideline on adult hypoglycemic disorders evaluation and critical sample concept

›International Hypoglycaemia Study Group definitions for clinically significant hypoglycemia below 3.0 mmol/L

›Toxicology references supporting octreotide for sulfonylurea-induced hypoglycemia with rebound prevention

›Resuscitation guidance emphasizing immediate glucose assessment and correction in altered mental status and seizures

Learn More: Hypoglycemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.